Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best schedule of vaccine therapy with or
without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid
tumors. Biological therapies, such as sirolimus, may stimulate the immune system in different
ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed
with tumor proteins may help the body build an effective immune response to kill tumor cells
that express NY-ESO-1. Infusing the vaccine directly into a lymph node may cause a stronger
immune response and kill more tumor cells. It is not yet known whether vaccine therapy works
better when given with or without sirolimus in treating solid tumors.